Top

Supportive Care in Cancer

Published in:

01-08-2019 | Review Article

Assessing cancer pain—the first step toward improving patients’ quality of life

Authors: Christian Minello, Brigitte George, Gilles Allano, Caroline Maindet, Alexis Burnod, Antoine Lemaire

Published in: Supportive Care in Cancer | Issue 8/2019

Abstract

Purpose

Numerous studies on cancer patients have shown that cancer pain still remains underestimated, poorly assessed, and under-treated. Pain relief should be considered as early as possible within personalized care and as an integral part of quality healthcare in many countries. Nevertheless, personalized care is still insufficiently taken into consideration, partly due to improper or incomplete assessment of cancer pain. The objective of this article is to propose a practical approach to this complex assessment, as the first step to improving patients’ quality of life.

Methods

Critical reflection based on literature analysis and clinical practice.

Results

Assessment of cancer pain means evaluating the pain intensity over time, the dimensions of pain (sensory-discriminative, cognitive, emotional, and behavioral), the pathophysiological nature of pain (neuropathic, nociceptive, and nociplastic), the etiology, and the patient’s perception (diffuse, localized, global). Cancer patients may have simple or multiple forms of pain (mixed, overlapped, combined, and associated). Furthermore, with the use of new specific therapies, the symptomatology of pain is also changing, and certain cancers are becoming chronic. Thus, cancer pain is an archetype of multimorphic pain, and its dynamic assessments (regular and repeated) require a multimodal and targeted approach in order to offer personalized pain management. Multimodal pain treatment must be adapted to the elements that disrupt cancer pain, to the patient’s cancer and to the specific treatments.

Conclusions

The dynamic assessments of pain demand the simplest, and the most complete possible procedure, to avoid feasibility problems or self-/hetero-assessment excesses that might lead to less precise and less reliable results. Multimodal and interdisciplinary approaches are being developed, making it possible to optimize cancer pain management.

Merskey H, Bogduk N (1994) Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the task force on taxonomy of the International Association for the Study of Pain, 2nd ed. IASP Press, Seattle

Ventafridda V, Tamburini M, Caraceni A, de Conno F, Naldi F (1987) A validation study of the WHO method for cancer pain relief. Cancer 59:850–856CrossRefPubMed

Van Den Beuken-Van Everdingen MHJ, Hochstenbach LMJ, Joosten EAJ et al (2016) Update on prevalence of pain in patients with Cancer: systematic review and meta-analysis. J Pain Symptom Manag 51:1070–1090.e9. https://doi.org/10.1016/j.jpainsymman.2015.12.340 CrossRef

Van Den Beuken-Van Everdingen MHJ, De Rijke JM, Kessels AG et al (2007) Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 18:1437–1449. https://doi.org/10.1093/annonc/mdm056 CrossRefPubMed

Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert AJ, Cohen R, Dow L (2009) Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol 20:1420–1433. https://doi.org/10.1093/annonc/mdp001 CrossRefPubMed

Institut national du Cancer (INCA) (2012) Synthèse de l’enquête nationale 2010 sur la prise en charge de la douleur chez des patients adultes atteints de cancer. www.e-cancer.fr/content/download/63502/571325/file/ENQDOUL12.pdf. Accessed 17 July 2018

Valeberg BT, Rustøen T, Bjordal K, Hanestad BR, Paul S, Miaskowski C (2008) Self-reported prevalence, etiology, and characteristics of pain in oncology outpatients. Eur J Pain 12:582–590. https://doi.org/10.1016/j.ejpain.2007.09.004 CrossRefPubMed

Greco MT, Roberto A, Corli O, Deandrea S, Bandieri E, Cavuto S, Apolone G (2014) Quality of cancer pain management: an update of a systematic review of undertreatment of patients with cancer. J Clin Oncol 32:4149–4154. https://doi.org/10.1200/JCO.2014.56.0383 CrossRefPubMed

Breuer B, Chang VT, Von Roenn JH et al (2015) How well do medical oncologists manage chronic cancer pain? A national survey. Oncologist 20:202–209. https://doi.org/10.1634/theoncologist.2014-0276 CrossRefPubMedPubMedCentral

10.

Mayor S (2000) Survey of patients shows that cancer pain still undertreated. BMJ 321:1309–1309. https://doi.org/10.1136/bmj.321.7272.1309/b CrossRefPubMedCentral

11.

MacDonald N, Ayoub J, Farley J, Foucault C, Lesage P, Mayo N (2002) A Quebec survey of issues in cancer pain management. J Pain Symptom Manag 23:39–47. https://doi.org/10.1016/S0885-3924(01)00374-8 CrossRef

12.

Hsieh RK (2005) Pain control in Taiwanese patients with cancer: a multicenter, patient-oriented survey. J Formos Med Assoc 104:913–919PubMed

13.

Efficace F, Bottomley A, Smit EF, Lianes P, Legrand C, Debruyne C, Schramel F, Smit H, Gaafar R, Biesma B, Manegold C, Coens C, Giaccone G, van Meerbeeck J, On behalf of the EORTC Lung Cancer Group and Quality of Life Unit (2006) Is a patient’s self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol 17:1698–1704. https://doi.org/10.1093/annonc/mdl183 CrossRefPubMed

14.

Armstrong AJ, Garrett-Mayer E, Ou Yang Y-C, Carducci MA, Tannock I, de Wit R, Eisenberger M (2007) Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 25:3965–3970. https://doi.org/10.1200/JCO.2007.11.4769 CrossRefPubMed

15.

Halabi S, Vogelzang NJ, Kornblith AB, Ou SS, Kantoff PW, Dawson NA, Small EJ (2008) Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 26:2544–2549. https://doi.org/10.1200/JCO.2007.15.0367 CrossRefPubMed

16.

Zylla D, Steele G, Gupta P (2017) A systematic review of the impact of pain on overall survival in patients with cancer. Support Care Cancer 25:1687–1698. https://doi.org/10.1007/s00520-017-3614-y CrossRefPubMed

17.

Treede R-D, Rief W, Barke A, et al (2015) A classification of chronic pain for ICD-11. https://doi.org/10.1097/j.pain.0000000000000160

18.

WHO Official Website. Available at: http://www.who.int/classifications/icd/revision/en/. Accessed 08 April 2019

19.

Syrjala KL, Jensen MP, Mendoza ME, Yi JC, Fisher HM, Keefe FJ (2014) Psychological and behavioral approaches to Cancer pain management. J Clin Oncol 32:1703–1711. https://doi.org/10.1200/JCO.2013.54.4825 CrossRefPubMedPubMedCentral

20.

Cassell E (2004) The nature of suffering and the goals of medicine, 2nd edn. Oxford University Press

21.

Lavand’homme P (2011) The progression from acute to chronic pain. Curr Opin Anaesthesiol 24:545–550. https://doi.org/10.1097/ACO.0b013e32834a4f74 CrossRefPubMed

22.

Fornasari D (2012) Pain mechanisms in patients with chronic pain. Clin Drug Investig 32:45–52. https://doi.org/10.2165/11630070-000000000-00000 CrossRefPubMed

23.

Latremoliere A, Woolf CJ (2009) Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain 10:895–926. https://doi.org/10.1016/J.JPAIN.2009.06.012 CrossRefPubMedPubMedCentral

24.

Coderre TJ, Katz J, Vaccarino AL, Melzack R (1993) Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain 52:259–285CrossRefPubMed

25.

Boureau F, Doubrère JF, Luu M (1990) Study of verbal description in neuropathic pain. Pain 42:145–152. https://doi.org/10.1016/0304-3959(90)91158-f CrossRefPubMed

26.

Portenoy R, Koh M (2010) Cancer pain syndromes. In: Bruera E, Portenoy RK (eds) Cancer pain. Assessment and management, vol 4. Cambridge University Press, Cambridge, pp 53–88

27.

Higginson IJ, Murtagh FEM (2010) Cancer pain epidemiology. In: Bruera E, Portenoy RK (eds) Cancer pain. Assessment and management, vol 3. Cambridge University Press, Cambridge, pp 37–52

28.

Zaza C, Baine N (2002) Cancer pain and psychosocial factors: a critical review of the literature. J Pain Symptom Manag 24:526–542. https://doi.org/10.1016/S0885-3924(02)00497-9 CrossRef

29.

National Institute for Health and Care Excellence (NICE) (2004) Guidance on cancer services improving supportive and palliative care for adults with cancer. The manual. ttps://www.nice.org.uk/guidance/csg4. Accessed 09 April 2019

30.

Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, Ripamonti CI, ESMO Guidelines Committee (2018) Management of cancer pain in adult patients: ESMO clinical practice guidelines†. Ann Oncol 29:iv166–iv191. https://doi.org/10.1093/annonc/mdy152 CrossRefPubMed

31.

Krakowski I, Theobald S, Balp L, Groupe de Travail SOR et al (2002) Standards, options and recommendations for the use of medical analgesics for the treatment of pain arising from excess nociception in adults with cancer (update 2002). Bull Cancer 89:1067–1074PubMed

32.

Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F, on behalf of the ESMO Guidelines Working Group (2012) Management of cancer pain: ESMO clinical practice guidelines. Ann Oncol 23:vii139–vii154. https://doi.org/10.1093/annonc/mds233 CrossRefPubMed

33.

Hui D, Bruera E (2014) A personalized approach to assessing and managing pain in patients with Cancer. J Clin Oncol 32:1640–1646. https://doi.org/10.1200/JCO.2013.52.2508 CrossRefPubMedPubMedCentral

34.

Street RL, Tancredi DJ, Slee C et al (2014) A pathway linking patient participation in cancer consultations to pain control. Psychooncology 23:1111–1117. https://doi.org/10.1002/pon.3518 CrossRefPubMed

35.

National Cancer Institute (2017) Cancer pain (PDQ®)–health professional version. https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq. Accessed 09 April 2019

36.

Bennett MI, Eisenberg E, Ahmedzai SH, Bhaskar A, O’Brien T, Mercadante S, Krčevski Škvarč N, Vissers K, Wirz S, Wells C, Morlion B (2018) Standards for the management of cancer-related pain across Europe. A position paper from the EFIC task force on Cancer pain. Eur J Pain 23:660–668. https://doi.org/10.1002/ejp.1346 CrossRef

37.

Berthold DR, Pond GR, Roessner M, de Wit R, Eisenberger M, Tannock IF, on behalf of the TAX-327 investigators (2008) Treatment of hormone-refractory prostate Cancer with docetaxel or Mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 14:2763–2767. https://doi.org/10.1158/1078-0432.CCR-07-0944 CrossRefPubMed

38.

Reddy A, Hui D, Bruera E (2012) A Successful Palliative Care Intervention for Cancer Pain Refractory to Intrathecal Analgesia. https://doi.org/10.1016/j.jpainsymman.2011.07.010

39.

Mejdahl MK, Andersen KG, Gärtner R et al (2013) Persistent pain and sensory disturbances after treatment for breast cancer: six year nationwide follow-up study. BMJ 346:f1865. https://doi.org/10.1136/bmj.f1865 CrossRefPubMed

40.

Wilkie DJ, Huang HY, Reilly N, Cain KC (2001) Nociceptive and neuropathic pain in patients with lung cancer: a comparison of pain quality descriptors. J Pain Symptom Manag 22:899–910CrossRef

41.

Ngamkham S, Holden JE, Wilkie DJ Differences in pain location, intensity and quality by pain pattern in outpatients with cancer. https://doi.org/10.1097/NCC.0b013e3181faab63

42.

Caraceni A, Portenoy RK (1999) An international survey of cancer pain characteristics and syndromes. Pain. 82:263–274. https://doi.org/10.1016/S0304-3959(99)00073-1 CrossRefPubMed

43.

Finnerup NB, Haroutounian S, Kamerman P, et al (2016) Neuropathic pain: an updated grading system for research and clinical practice. https://doi.org/10.1097/j.pain.0000000000000492

44.

Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpää M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice ASC, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M (2015) Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 14:162–173. https://doi.org/10.1016/S1474-4422(14)70251-0 CrossRefPubMedPubMedCentral

45.

Swarm RA, Abernethy AP, Anghelescu DL, Benedetti C, Buga S, Cleeland C, Deleon-Casasola OA, Eilers JG, Ferrell B, Green M, Janjan NA, Kamdar MM, Levy MH, Lynch M, McDowell R, Moryl N, Nesbit SA, Paice JA, Rabow MW, Syrjala KL, Urba SG, Weinstein SM, Dwyer M, Kumar R, National Comprehensive Cancer Network (2013) Adult cancer pain. J Natl Compr Cancer Netw 11:992–1022CrossRef

46.

Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G, Science Committee of the Association for Palliative Medicine of Great Britain and Ireland (2009) The management of cancer-related breakthrough pain: recommendations of a task group of the science Committee of the Association for palliative medicine of Great Britain and Ireland. Eur J Pain 13:331–338. https://doi.org/10.1016/j.ejpain.2008.06.014 CrossRefPubMed

47.

Haute Autorité de Santé (HAS) (2014) Les médicaments des accès douloureux paroxystiques du cancer. https://www.has-sante.fr/portail/upload/docs/application/pdf/2014-07/fbum_adp_maj_juillet2014.pdf. HAS (2014) Les médicaments des accès douloureux paroxystiques du cancer. Accessed 09 April 2019

48.

Mercadante S, Radbruch L, Caraceni A, Cherny N, Kaasa S, Nauck F, Ripamonti C, de Conno F, Steering Committee of the European Association for Palliative Care (EAPC) Research Network (2002) Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 94:832–839CrossRefPubMed

49.

American Pain Foundation AP (2011) Breakthrough Cancer pain: mending the break in the continuum of care. J Pain Palliat Care Pharmacother 25:252–264. https://doi.org/10.3109/15360288.2011.599920 CrossRef

50.

Poulain P, Filbet M, Ammar D, Morere JF, Krakowski I, Delorme C, Serrie A (2012) Caractéristiques et traitements des accès douloureux paroxystiques (ADPc) chez les patients cancéreux : résultats de l’enquête ADEPI. Douleurs Eval Diagnostic Trait 13:163–168. https://doi.org/10.1016/j.douler.2012.07.002 CrossRef

51.

Løhre ET, Klepstad P, Bennett MI, Brunelli C, Caraceni A, Fainsinger RL, Knudsen AK, Mercadante S, Sjøgren P, Kaasa S (2016) Authors’ reply to Davies et al. J Pain Symptom Manag 52:e1–e2. https://doi.org/10.1016/j.jpainsymman.2016.06.003 CrossRef

52.

Løhre ET, Klepstad P, Bennett MI, Brunelli C, Caraceni A, Fainsinger RL, Knudsen AK, Mercadante S, Sjøgren P, Kaasa S, European Association for Palliative Care Research Network (2016) From “breakthrough” to “episodic” Cancer pain? A European Association for Palliative Care Research Network Expert Delphi Survey toward a common terminology and classification of transient Cancer pain exacerbations. J Pain Symptom Manag 51:1013–1019. https://doi.org/10.1016/j.jpainsymman.2015.12.329 CrossRef

53.

Portenoy RK, Bruns D, Shoemaker B, Shoemaker SA (2010) Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics. J Opioid Manag 6:97–108CrossRefPubMed

54.

Svendsen KB, Andersen S, Arnason S, Arnér S, Breivik H, Heiskanen T, Kalso E, Kongsgaard UE, Sjogren P, Strang P, Bach FW, Jensen TS (2005) Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 9:195–206. https://doi.org/10.1016/j.ejpain.2004.06.001 CrossRefPubMed

55.

Zeppetella G, O’Doherty CA, Collins S (2000) Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manag 20:87–92CrossRef

56.

Portenoy RK, Payne D, Jacobsen P (1999) Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81:129–134CrossRefPubMed

57.

Fortner BV, Okon TA, Portenoy RK (2002) A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain 3:38–44CrossRefPubMed

58.

Davies A, Buchanan A, Zeppetella G, Porta-Sales J, Likar R, Weismayr W, Slama O, Korhonen T, Filbet M, Poulain P, Mystakidou K, Ardavanis A, O’Brien T, Wilkinson P, Caraceni A, Zucco F, Zuurmond W, Andersen S, Damkier A, Vejlgaard T, Nauck F, Radbruch L, Sjolund KF, Stenberg M (2013) Breakthrough Cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manag 46:619–628. https://doi.org/10.1016/j.jpainsymman.2012.12.009 CrossRef

59.

Strada E, Portenoy R (2017) Psychological, rehabilitative, and integrative therapies for cancer pain. Uptodate. https://www.uptodate.com/contents/psychological-rehabilitative-and-integrative-therapies-for-cancer-pain#H44713544. Accessed 17 July 2018

60.

Adam R, Burton CD, Bond CM, de Bruin M, Murchie P (2017) Can patient-reported measurements of pain be used to improve cancer pain management? A systematic review and meta-analysis. BMJ Support Palliat Care 7:00.1-00. https://doi.org/10.1136/bmjspcare-2016-001137 CrossRef

61.

Caraceni A, Cherny N, Fainsinger R et al (2002) Pain measurement tools and methods in clinical research in palliative care: recommendations of an Expert Working Group of the European Association of Palliative Care. J Pain Symptom Manage 23:239–255CrossRefPubMed

62.

Melzack R (1975) The McGill pain questionnaire: major properties and scoring methods. Pain 1:277–299CrossRefPubMed

63.

Cleeland CS, Ryan KM (1994) Pain assessment: global use of the brief pain inventory. Ann Acad Med Singap 23:129–138PubMed

64.

Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370CrossRefPubMed

65.

Brooks R (1996) EuroQol: the current state of play. Health Policy 37:53–72CrossRefPubMed

66.

Ware JE, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473–483CrossRefPubMed

67.

Ratl P, Jouvel E, Pickeringl G, Donnarell L, Nguyenl L, Michell M, Capriz-Ribièrel F, Lefebvre-Chapirol S, Gauquelinl F, Bonin-Guillaumel S (2011) Validation of an acute pain-behavior scale for older persons with inability to communicate verbally: Algoplus®. Eur J Pain 15:198.e1–198.e10. https://doi.org/10.1016/j.ejpain.2010.06.012 CrossRef

68.

Lefebvre-Chapiro S (2001) The Doloplus 2 scale – evaluating pain in the elderly. Eur J Palliat Care 8:191–194

69.

Morello R, Jean A, Alix M, Sellin-Peres D, Fermanian J (2007) A scale to measure pain in non-verbally communicating older patients: the EPCA-2. Pain 133:87–98. https://doi.org/10.1016/j.pain.2007.03.007 CrossRefPubMed

70.

Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, Cunin G, Fermanian J, Ginies P, Grun-Overdyking A, Jafari-Schluep H, Lantéri-Minet M, Laurent B, Mick G, Serrie A, Valade D, Vicaut E (2005) Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 114:29–36. https://doi.org/10.1016/j.pain.2004.12.010 CrossRefPubMed

71.

Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, Rostaing S, Lanteri-Minet M, Collin E, Grisart J, Boureau F (2004) Development and validation of the neuropathic pain symptom inventory. Pain 108:248–257. https://doi.org/10.1016/j.pain.2003.12.024 CrossRefPubMed

72.

Attal N, Bouhassira D, Baron R (2018) Diagnosis and assessment of neuropathic pain through questionnaires. Lancet Neurol 17:456–466. https://doi.org/10.1016/S1474-4422(18)30071-1 CrossRefPubMed

73.

Farrar JT, Young JP, LaMoreaux L et al (2001) Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94:149–158CrossRefPubMed

74.

Herr K, Coyne PJ, McCaffery M, Manworren R, Merkel S (2011) Pain assessment in the patient unable to self-report: position statement with clinical practice recommendations. Pain Manag Nurs 12:230–250. https://doi.org/10.1016/j.pmn.2011.10.002 CrossRefPubMed

75.

Miguel R (2000) Interventional treatment of Cancer pain: the fourth step in the World Health Organization analgesic ladder? Cancer Control 7:149–156. https://doi.org/10.1177/107327480000700205 CrossRefPubMed

76.

Buga S, Sarria JE (2012) The management of pain in metastatic bone disease. Cancer Control 19:154–166. https://doi.org/10.1177/107327481201900210 CrossRefPubMed

77.

Institute of Medicine (2001) Crossing the quality chasm: a new health system for the 21st century. IOM Washington, DC. http://www.nationalacademies.org/hmd/~/media/Files/Report%20Files/2001/Crossing-the-Quality-Chasm/Quality%20Chasm%202001%20%20report%20b

78.

Department of Health (2008) High quality care for all: NHS next stage review final report. DH, London. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/228836/7432.pdf. Accessed 8 Apr 2019

79.

Haute Autorité de Santé (HAS) (2015) Healthcare organisations accreditation programme in France. http://www.has-sante.fr/portail/jcms/c_2044304/en/healthcare-organisations-accreditation-programme-in-france. Accessed 9 Apr 2019

80.

Ministère de la santé et des Affaires Sociales (2006) Plan d’amélioration de la prise en charge de la douleur - 2006–2010. http://solidarites-sante.gouv.fr/IMG/pdf/Plan_d_amelioration_de_la_prise_en_charge_de_la_douleur_2006-2010_.pdf. Accessed 9 Apr

81.

Groene O, Arah OA, Klazinga NS, et al (2015) Patient Experience Shows Little Relationship with Hospital Quality Management Strategies. https://doi.org/10.1371/journal.pone.0131805

82.

Cherny NI, Catane R, Kosmidis P (2003) ESMO takes a stand on supportive and palliative care. Ann Oncol 14:1335–1337. https://doi.org/10.1093/annonc/mdg379 CrossRefPubMed

83.

Hui D, Bruera E (2015) Models of integration of oncology and palliative care. Ann Palliat Med 4:89–98. https://doi.org/10.3978/j.issn.2224-5820.2015.04.01 CrossRefPubMed

84.

Witt CM, Balneaves LG, Cardoso MJ, Cohen L, Greenlee H, Johnstone P, Kücük Ö, Mailman J, Mao JJ (2017) A comprehensive definition for integrative oncology. JNCI Monogr 2017. https://doi.org/10.1093/jncimonographs/lgx012

Title: Assessing cancer pain—the first step toward improving patients’ quality of life
Authors: Christian Minello
Brigitte George
Gilles Allano
Caroline Maindet
Alexis Burnod
Antoine Lemaire
Publication date: 01-08-2019
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 8/2019
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-019-04825-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2019

Association between glycemic control, age, and outcomes among intensively treated patients with acute myeloid leukemia

Cancer patients’ needs for virtues and physicians’ characteristics in physician-patient communication: a survey among patient representatives

A nationwide survey of adherence to analgesic drugs among cancer patients in Taiwan: prevalence, determinants, and impact on quality of life

A clinical approach to the management of cancer-related pain in emergency situations

Strategies for interventional therapies in cancer-related pain—a crossroad in cancer pain management

Trajectory of severity of postoperative delirium symptoms and its prospective association with cognitive function in patients with gastric cancer: results from a prospective observational study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer